Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment
Nephrology · 2026
DOI: 10.1111/nep.70292 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology, 2026. Verfasst von Ryo Matsuura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Endocrinology, Graduate School of Internal Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Tolvaptan, Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists, Kidney. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Otsuka Pharmaceutical Development and Commercialization, Inc., Otsuka Pharmaceutical Development and Commercialization.
Abstract (Originalsprache)
Aim
Tolvaptan delays growth in total kidney volume (TKV) and decline in estimated glomerular filtration rate (eGFR) among individuals with autosomal dominant polycystic kidney disease (ADPKD) at elevated risk of rapid progression. We evaluated changes in urine osmolality (Uosm) after treatment initiation as a potential biomarker of long‐term response.
Methods
This was a post hoc analysis of TEMPO 3:4, a 3‐year, randomized, placebo‐controlled trial of tolvaptan. Causal mediation analysis assessed if the effect of tolvaptan on longer‐term outcomes of change in eGFR and TKV at month 36 was mediated by change in Uosm at week 3. Analyses were performed separately for non‐Japanese and Japanese participants.
Results
The average causal mediation effect (ACME) of change in Uosm on eGFR at month 36 was statistically significant (2.4; 95% quasi‐Bayesian confidence interval [CI] 1.2, 3.6) in the non‐Japanese cohort ( n = 948). In the Japanese cohort ( n = 138), whereas the ACME for change in Uosm was non‐significant (−0.3 [95% CI: −2.3, 1.7]), the average direct effect (ADE) of tolvaptan on eGFR was statistically significant (8.4 [95% CI 3.1, 12.4]). For percentage change in TKV, the ADE of tolvaptan was statistically significant in both the non‐Japanese (−8.3 [95% CI: −10.5, −6.3]) and Japanese cohorts (−12.0 [95% CI: −17.4, −7.5]).
Conclusion
This study supported short‐term change in Uosm as a predictive biomarker of longer‐term kidney function in a non‐Japanese cohort; the relationship was not significant in the smaller Japanese cohort. Tolvaptan exhibited a direct treatment effect on the growth of kidney volume in both cohorts of ADPKD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Endocrinology, Graduate School of Internal Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, Tokyo, Japan.
- Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey, USA.
- Department of Haemodialysis and Apheresis, The University of Tokyo Hospital, Tokyo, Japan.
ORCID-Profile: Ryo Matsuura, Sachin Hajarnis, Yoshifumi Hamasaki
Förderung
- Otsuka Pharmaceutical Development and Commercialization, Inc.
- Otsuka Pharmaceutical Development and Commercialization
Zitieren
APA
Matsuura, R., Doi, K., Zhang, Z., Maringer, K., Hajarnis, S., & Hamasaki, Y. (2026). Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment. Nephrology. https://doi.org/10.1111/nep.70292
Vancouver
Matsuura R, Doi K, Zhang Z, Maringer K, Hajarnis S, Hamasaki Y. Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment. Nephrology. 2026. doi:10.1111/nep.70292
BibTeX
@article{Matsuura2026,
author = {Matsuura, Ryo and Doi, Kent and Zhang, Zhen and Maringer, Katherine and Hajarnis, Sachin and Hamasaki, Yoshifumi},
title = {Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment},
journal = {Nephrology},
year = {2026},
doi = {10.1111/nep.70292}
}
EUVIMED